The latest price target for Evaxion Biotech (NASDAQ:EVAX) was reported by HC Wainwright & Co. on November 1, 2024. The analyst firm set a price target for $14.00 expecting EVAX to rise to within 12 months (a possible 686.52% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Evaxion Biotech (NASDAQ:EVAX) was provided by HC Wainwright & Co., and Evaxion Biotech reiterated their buy rating.

The last upgrade for Evaxion Biotech AS happened on April 2, 2024 when Ladenburg Thalmann raised their price target to $8. Ladenburg Thalmann previously had a neutral for Evaxion Biotech AS.

The last downgrade for Evaxion Biotech AS happened on December 21, 2023 when Ladenburg Thalmann changed their price target from N/A to N/A for Evaxion Biotech AS.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evaxion Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evaxion Biotech was filed on November 1, 2024 so you should expect the next rating to be made available sometime around November 1, 2025.

While ratings are subjective and will change, the latest Evaxion Biotech (EVAX) rating was a reiterated with a price target of $14.00 to $14.00. The current price Evaxion Biotech (EVAX) is trading at is $1.78, which is out of the analyst’s predicted range.